Pharmacokinetics of isradipine in patients with chronic liver disease

Details

Serval ID
serval:BIB_51EB9B32E054
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Pharmacokinetics of isradipine in patients with chronic liver disease
Journal
European Journal of Clinical Pharmacology
Author(s)
Cotting  J., Reichen  J., Kutz  K., Laplanche  R., Nuesch  E.
ISSN
0031-6970 (Print)
Publication state
Published
Issued date
1990
Volume
38
Number
6
Pages
599-603
Notes
Journal Article
Research Support, Non-U.S. Gov't
Abstract
The pharmacokinetics of the dihydropyridine calcium antagonist isradipine has been examined in 8 healthy volunteers, 7 patients with non-cirrhotic chronic liver disease (CLD), and 8 patients with biopsy-proven cirrhosis (CIR). Isradipine was simultaneously given orally (12C 5 mg) and i.v. (13C 1 mg). Systemic availability was significantly increased from 17% to 16% in controls and CLD, respectively, to 37% in CIR. The corresponding systemic clearances averaged 1.1, 0.9 and 0.6 l.min-1, the reduction in cirrhotics being significant. Both aminopyrine demethylation capacity, a measure of hepatic microsomal function, and indocyanine green disappearance, a measure of hepatic perfusion, were correlated with the reduction in systemic clearance, and the reduction in oral clearance was correlated with the reciprocal of the serum bile acid concentration. The loss of first-pass extraction should be considered when this calcium antagonist is given perorally in patients with hepatic cirrhosis.
Keywords
Administration, Oral Adult Aminopyrine/metabolism Bile Acids and Salts/metabolism Biotransformation Chronic Disease Hepatitis/metabolism Humans Indocyanine Green/diagnostic use Injections, Intravenous Isradipine Liver Diseases/*metabolism Liver Function Tests Male Middle Aged Models, Biological Pyridines/administration & dosage/adverse effects/*pharmacokinetics
Pubmed
Web of science
Create date
24/01/2008 16:41
Last modification date
20/08/2019 14:07
Usage data